ABUS vs SRPT · P/E 5.4, rev $6.2M vs rev $1.90B
Arbutus Biopharma Corp (ABUS) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the ABUS and SRPT stock pages for the full models.
Not investment advice.